A1F hosts the Grants Award Reception at the 2026 AASLD The Liver Meeting

The Alpha-1 Foundation (A1F) was proud to exhibit at the 2026 AASLD The Liver Meeting from November 5-9 in Denver, Colorado. The American Association for the Study of Liver Diseases is the premier medical organization in the United States for physicians, scientists and healthcare professionals dedicated to preventing and curing liver diseases. The Liver Meeting is an annual international conference where leading researchers share new clinical trials and scientific breakthroughs in hepatology.  

A1F presented an abstract poster titled “Alpha-1 Foundation Research Registry: Liver Affected Alpha-1 Antitrypsin Deficiency Patients and Workplace Toxin Exposure in the United States” to kick off the meeting on Thursday. Additionl Alpha-1 Antitrypsin Deficiency (Alpha-1) sessions included “Gene-Based Therapy in Liver Disease-Promise, Ethics, and Responsibilities” led by Lorenzo D’Antiga, Jeffery Teckman, “Where Liver Meets Lung: Coordinating Modern AATD Care” led by Virginia C Clark, Raj Vuppalanchi, Brooks T Kuhn and “Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries: Presentations: Beyond Cirrhosis: Major Adverse Liver Outcomes Across PIMZ, PISZ, and PIZZ Genotypes in Alpha-1 Antitrypsin Deficiency” led by Dustin Bastaich, PhD. 

A1F also hosted its annual AASLD Grants Award Reception recognizing liver researchers whose work is helping advance scientific understanding of Alpha-1 and support future discoveries in liver disease and related research. Jon Hagstrom, Chair of the A1F Board of Directors and Dr. Virginia Clark, A1F Board of Directors Physician Director introduced and acknowledged the grant award recipients in attendance. Thank you Katrin Panzitt, PhD from Medical University of Graz, Austria, Martin Wagner, MD from Medical University of Graz, Austria and Shah Hussain, PhD, MBA from University of Alabama at Birmingham, USA for your continued dedication to the A1F mission.  

This past April, the Grants Advisory Committee awarded 20 in-cycle grants to well-deserving applicants totaling over $3.8 million. Our research portfolio continues to strike a balance between lung and liver research, with 64% of the effort concentrated on lung research and 36% on liver research. Thank you to the Grant Award Reception sponsors, AlphaNet, CSL, Grifols and Takeda.  

“A1F is at an exhilarating and critical moment for our community. There are now numerous new potential therapeutics in the pipeline with diverse mechanisms of action, and I am optimistic that one or more of these treatments will prove beneficial in upcoming clinical trials,” said Jon Hagstrom, A1F Board of Directors Chair. 

A1F is working thoughtfully and with urgency on many fronts to realize this vision. The ecosystem continues to grow as A1F deepens its support for research infrastructure, expands engagement with emerging therapy companies, and strengthens the systems that help connect patients, investigators, and clinical development opportunities.  

“The importance of discovery remains high. Funding scientific research, as we celebrate tonight, is a critical part of this approach. Many researchers who have devoted their careers to Alpha-1 research might not be doing so without the support they have received from the Alpha-1 Foundation over the years,” said Dr. Virginia Clark, A1F Board of Directors, Physician Director. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.